On Jul. 22, 2020, Altimmune announced an agreement with Vigene Biosciences to manufacture AdCOVIDTM, Altimmuneﾒs single-dose intranasal vaccine candidate for COVID-19. Vigene, a Rockville, Maryland-based Contract Development and Manufacturing Organization (CDMO), specializes in viral vectors and will deploy its capabilities to manufacture AdCOVID. Following positive pre-clinical data, Altimmune planned to start a Phase 1 clinical trial of AdCOVID in Q4 2020.